HMG CoA reductase inhibitor suppresses the expression of tissue factor and plasminogen activator inhibitor-1 induced by angiotensin II in cultured rat aortic endothelial cells. 2003

Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
Second Department of Medicine, Kyoto Prefectural University of Medicine, 465 Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto 602-8566, Japan.

BACKGROUND It has been demonstrated that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (HRIs) reduce the incidence of acute cardiovascular events in patients with hyperlipidemia. Recent reports have shown that the protective effects of these drugs against cardiovascular events are also observed in patients without hyperlipidemia, but the mechanism of this favorable effect still remains unclear. In this study, the effects of HRIs on the endothelial regulation of thrombus formation were elucidated. RESULTS The mRNA and protein expression of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) induced by angiotensin II (Ang II) were evaluated in cultured rat aortic endothelial cells. Pretreatment with simvastatin (0.03-3 microg/ml) significantly inhibited TF and PAI-1 induction by Ang II in a dose- and time-dependent manner. These inhibitions were significantly attenuated by mevalonic acid or geranylgeranyl pyrophosphate. Both Rho inhibitor, C3 exoenzyme, and Rho kinase inhibitor, Y-27632, mimicked the inhibitory effects of simvastatin against TF and PAI-1 induced by Ang II. This result suggested that the Rho/Rho kinase pathway is related to the TF and PAI-1 induction by Ang II. CONCLUSIONS It was indicated that simvastatin maintains endothelial cells to be antithrombotic by inhibiting TF and PAI-1 expression via the Rho/Rho kinase pathways in which AngII induces TF and PAI-1 expression. These observations explain, at least partly, the mechanism of the favorable effects of simvastatin in reducing the thrombotic events.

UI MeSH Term Description Entries
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004730 Endothelium, Vascular Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. Capillary Endothelium,Vascular Endothelium,Capillary Endotheliums,Endothelium, Capillary,Endotheliums, Capillary,Endotheliums, Vascular,Vascular Endotheliums
D005786 Gene Expression Regulation Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control (induction or repression) of gene action at the level of transcription or translation. Gene Action Regulation,Regulation of Gene Expression,Expression Regulation, Gene,Regulation, Gene Action,Regulation, Gene Expression
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001011 Aorta The main trunk of the systemic arteries. Aortas
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D013925 Thromboplastin Constituent composed of protein and phospholipid that is widely distributed in many tissues. It serves as a cofactor with factor VIIa to activate factor X in the extrinsic pathway of blood coagulation. Antigens, CD142,CD142 Antigens,Coagulation Factor III,Factor III,Tissue Factor,Tissue Thromboplastin,Blood Coagulation Factor III,Coagulin,Glomerular Procoagulant Activity,Prothrombinase,Tissue Factor Procoagulant,Urothromboplastin,Activity, Glomerular Procoagulant,Factor III, Coagulation,Procoagulant Activity, Glomerular,Procoagulant, Tissue Factor,Thromboplastin, Tissue
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
March 1998, Thrombosis and haemostasis,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
June 1997, Thrombosis and haemostasis,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
February 2000, Arteriosclerosis, thrombosis, and vascular biology,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
July 1994, Circulation,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
February 2008, Atherosclerosis,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
April 1999, British journal of clinical pharmacology,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
December 2002, Japanese journal of pharmacology,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
July 1991, The Journal of biological chemistry,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
June 2002, Journal of cardiovascular pharmacology,
Yasufumi Kunieda, and Katsumi Nakagawa, and Hiromi Nishimura, and Hisato Kato, and Naoki Ukimura, and Shingo Yano, and Hidehiko Kawano, and Shinzo Kimura, and Masao Nakagawa, and Hajime Tsuji
March 1994, Science in China. Series B, Chemistry, life sciences & earth sciences,
Copied contents to your clipboard!